Docoh
Loading...

BMY Bristol-Myers Squibb

APP
Utility
Phenylpyrrolidinone Formyl Peptide 2 Receptor Agonists
2 Dec 21
Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
Filed: 12 Aug 21
APP
Utility
Crystal Form of 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE
2 Dec 21
Disclosed is crystalline Form A of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d3)pyridazine-3-carboxamide.
Yanlei Zhang, Michael A. Galella
Filed: 11 Aug 21
GRANT
Utility
Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
30 Nov 21
The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
Filed: 27 Feb 19
GRANT
Utility
Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
30 Nov 21
Nicholas R. Wurtz, Pravin Sudhakar Shirude, Andrew Quoc Viet
Filed: 8 Jun 18
APP
Utility
Methods of Treating Cancer with Antibodies Against TIM3
25 Nov 21
This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti-TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway (e.g., anti-PD-1 antibody).
Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Guodong CHEN, Michelle Renne KUHNE, Hong-An TRUONG, Poliana PATAH, Jeffrey R. JACKSON, Ronald A. FLEMING
Filed: 15 Jan 19
APP
Utility
Combination Therapy Using an ANTI-FUCOSYL-GM1 Antibody and an ANTI-CD137 Antibody
25 Nov 21
This disclosure provides combination therapy for treating a subject, such as a subject afflicted with a lung cancer, comprising administering to the subject an anti-fucosyl-GM1 antibody and an anti-CD137 antibody, or antigen-binding portions of either or both.
Josephine M. CARDARELLI, Daniel E. LOPES de MENEZES, Paul D. PONATH, Bingliang CHEN, Chin PAN
Filed: 28 Jul 21
GRANT
Utility
Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
23 Nov 21
Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Tasir S. Haque, Michael A. Poss, Louis J. Lombardo, John E. Macor, Laxman Pasunoori, Sreekantha Ratna Kumar
Filed: 27 Jul 17
GRANT
Utility
Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
23 Nov 21
Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Hao Zhang, Yan Shi, Jun Li
Filed: 18 Dec 18
GRANT
Utility
Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
23 Nov 21
Joanne M. Smallheer, Nicholas R. Wurtz, Meriah Neissel Valente, Karen A. Rossi, Ellen K. Kick
Filed: 8 Jun 18
GRANT
Utility
Antibody polypeptides that antagonize CD40L
23 Nov 21
Antibody polypeptides that specifically bind human CD40L are provided.
Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
Filed: 12 Dec 18
APP
Utility
Inhibitors of Indoleamine 2,3-DIOXYGENASE and Methods of Their Use
18 Nov 21
James Aaron BALOG, Steven P. SEITZ, Jay A. MARKWALDER, David K. WILLIAMS, Weifang SHAN, Susheel Jethanand NARA, Saumya ROY, Srinivas CHERUKU, Nagalakshmi PULICHARLA
Filed: 20 Jul 19
GRANT
Utility
PD-L1 binding polypeptides for imaging
16 Nov 21
Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
Paul E. Morin, David Donnelly, Dasa Lipovsek, Jochem Gokemeijer, Maria Jure-Kunkel, David Fabrizio, Martin C. Wright, Douglas Dischino, Samuel J. Bonacorsi, Jr., Ralph Adam Smith, Virginie LaFont, Daniel Cohen
Filed: 24 Jul 19
GRANT
Utility
Treatment of cancer with TOR kinase inhibitors
9 Nov 21
Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
Shuichan Xu, Kristen Mae Hege, Heather Raymon, Rama K. Narla, Rajesh Chopra
Filed: 20 Feb 18
GRANT
Utility
Isofuranone compounds useful as HPK1 inhibitors
9 Nov 21
Erika M. V. Araujo, Yan Chen, Bireshwar Dasgupta, Andrew P. Degnan, Matthew D. Hill, Godwin Kwame Kumi, Harold A. Mastalerz, Mark D. Wittman, Bradley C. Pearce, Guifen Zhang
Filed: 5 Nov 18
GRANT
Utility
Alkene compounds as farnesoid x receptor modulators
9 Nov 21
Joseph E. Carpenter, Matthias Broekema, Jianxin Feng, Chunjian Liu, Wei Wang, Ying Wang
Filed: 31 Oct 18
APP
Utility
Combination Therapy for Melanoma
4 Nov 21
The invention provides a method of treating a previously untreated metastatic or unresectable melanoma.
Matthew MAURER, Katy L. SIMONSEN
Filed: 18 Oct 19
APP
Utility
Miniaturized Dystrophins Having Spectrin Fusion Domains and Uses Thereof
4 Nov 21
Disclosed herein are nucleic acid molecules, polypeptides, cells, vectors, and pharmaceutical compositions relating to miniaturized dystrophin.
Glen BANKS, Jonathan Harry DAVIS, Paul Charles LEVESQUE
Filed: 28 Apr 21
APP
Utility
Compositions Comprising a Combination of an ANTI-LAG-3 Antibody, a PD-1 Pathway Inhibitor, and an Immunotherapeutic Agent
4 Nov 21
Provided are methods for clinical treatment of malignant tumors (e.g., advanced solid tumors) using a combination of an anti-LAG-3 antibody, an anti-PD-1 antibody, and an immunotherapeutic agent.
Alan J. KORMAN, Nils LONBERG, Mark J. SELBY, Jeffrey JACKSON
Filed: 30 May 18
GRANT
Utility
Benzofuran derivatives for the treatment of hepatitis C
2 Nov 21
Kap-Sun Yeung, John F. Kadow, Rajesh Onkardas Bora, Prakash Anjanappa, Kumaravel Selvakumar, Samayamunthula Venkata Satya Arun Kumar Gupta
Filed: 17 Mar 17
GRANT
Utility
Fibronectin based scaffold proteins having improved stability
2 Nov 21
The present application provides fibronectin based scaffold proteins associated with improved stability.
Ray Camphausen, John O'Loughlin, Bernice Yeung, Yihong Zhang
Filed: 11 Mar 19
Patents are sorted by USPTO publication date, most recent first